Tech Center 1600 • Art Units: 1646 1674
This examiner grants 63% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17416403 | METHOD OF TREATING CANCER USING A HISTONE ACETYLTRANSERACE ACTIVATOR WITH IFN¿ AND AN IMMUNE CHECKPOINT INHIBITOR | Non-Final OA | The Regents of the University of California |
| 18019467 | TREATMENT OF CLL | Final Rejection | NOVARTIS AG |
| 18019469 | TREATMENT OF B CELL MALIGNANCIES | Final Rejection | NOVARTIS AG |
| 17773935 | TREATMENT FOR SJÖGREN'S SYNDROME USING AN ANTI-BAFFR ANTIBODY | Non-Final OA | NOVARTIS AG |
| 17921793 | PHARMACEUTICAL FORMULATION | Non-Final OA | AMGEN INC. |
| 18429887 | Methods of Treating Multiple Myeloma with Bispecific Anti-BCMA x Anti-CD3 Antibodies | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17999271 | Antibody Variants with Improved Pharmacokinetic Properties | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 17905870 | ANTIBODIES TO CD40 WITH ENHANCED AGONIST ACTIVITY | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 18473695 | MANAbodies AND METHODS OF USING | Final Rejection | The Johns Hopkins University |
| 17907312 | TNFa SIGNALING TRIGGERS TUMOR-PROMOTING INFLAMMATION THAT CAN BE TARGETED TO THERAPY | Non-Final OA | Baylor College of Medicine |
| 18003118 | SULFATED PEPTIDES FOR CHEMOKINE RECEPTOR ANTIBODY GENERATION | Non-Final OA | BAYER HEALTHCARE LLC |
| 17270231 | ANTIBODY FOR PURE ISOLATION OF VASCULAR ENDOTHELIAL CELLS AND PREPARATION METHOD THEREOF | Final Rejection | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 18666512 | CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONS | Non-Final OA | Bayer Aktiengesellschaft |
| 18666545 | CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONS | Non-Final OA | Bayer Aktiengesellschaft |
| 18508346 | BINDING MOLECULES FOR THE TREATMENT OF CANCER | Non-Final OA | Boehringer Ingelheim International GmbH |
| 17414970 | BIFUNCTIONAL ANTI-PD-1/IL-7 MOLECULE | Non-Final OA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
| 18731402 | Chimeric Natural Killer Cell Receptors and Method of Using Thereof | Non-Final OA | ST PHI THERAPEUTICS CO., LTD. |
| 18043602 | Combination Therapy of a PD-1 Antagonist and an Antagonist for VEGFR-2 for Treating Patients with Cancer | Non-Final OA | MSD International GmbH |
| 18638420 | ANTI-BCMA ANTIBODIES AND TREATMENT METHODS | Final Rejection | SUTRO BIOPHARMA, INC. |
| 17972867 | MONOCLONAL ANTIBODIES AGAINST C-MET | Non-Final OA | Genmab A/S |
| 18019612 | COMBINED MEDICATION FOR TREATING SOFT TISSUE SARCOMA | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 17280550 | METHODS AND PHARMACEUTICAL COMPOSITION COMPRISING TAFA4 FOR REDUCING SKIN INFLAMMATION | Final Rejection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) |
| 17817033 | MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137 | Non-Final OA | BioNTech SE |
| 18140892 | CRTAM ANTIBODIES AND METHODS OF TREATING CANCER | Final Rejection | Oxford BioTherapeutics Ltd |
| 18246939 | ANTI-CLAUDIN18.2 AND CD3 BISPECIFIC ANTIBODY AND USE THEREOF | Non-Final OA | FORTVITA BIOLOGICS (SINGAPORE) PTE. LTD. |
| 18010944 | ANTI-CLAUDIN18.2 ANTIBODY AND USE THEREOF | Non-Final OA | FORTVITA BIOLOGICS (SINGAPORE) PTE. LTD. |
| 18021382 | CD40 AGONISTIC ANTIBODY AND METHOD OF USE | Non-Final OA | WUXI BIOLOGICS (SHANGHAI) CO. LTD. |
| 17928136 | ANTIBODIES SPECIFICALLY RECOGNIZING NERVE GROWTH FACTOR AND USES THEREOF | Non-Final OA | STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD. |
| 18150428 | METHOD OF TREATING CANCER USING ANTI-PD-1/CD40 BISPECIFIC ANTIBODIES | Non-Final OA | Eucure (Beijing) Biopharma Co., Ltd. |
| 18013504 | ANTI-GITR MONOCLONAL ANTIBODY AND MEDICAL USE THEREOF | Non-Final OA | INNOLAKE BIOPHARMA (HANGZHOU) CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy